RECURSION PHARMACEUTICALS

Insider Sale by Borgeson Blake Sparks Buzz & Insight on Recursion’s AI‑Driven Biotech Strategy

Explore how Borgeson Blake’s July 7 2026 sale of 40,000 Recursion Pharma shares reveals insider strategy, market sentiment, and AI‑driven drug‑discovery prospects.

RECURSION PHARMACEUTICALS
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

10/07/2026, 00:20

4 minutes to read

Recursion Insider Buying Surge Signals Potential Upside Amid Current Low

Insider buy by Recursion board member Dar Zavain signals confidence in the AI‑drug platform; watch for pipeline milestones that could lift the stock.

RECURSION PHARMACEUTICALS
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

03/07/2026, 00:14

3 minutes to read